News
EDSA
4.468
+3.68%
0.158
Weekly Report: what happened at EDSA last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at EDSA last week (0408-0412)?
Weekly Report · 04/15 10:51
Edesa Biotech Showcases Innovation at Investor Conference
TipRanks · 04/11 20:37
Weekly Report: what happened at EDSA last week (0401-0405)?
Weekly Report · 04/08 10:56
RPT-BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. Wall Street concerned increased use of weight-loss drugs will crimp sales of U.S. Food companies. Analysts expect CAG to post a rev decline of 2.5% in Q3.
Reuters · 04/04 09:00
BUZZ-PREVIEW: Conagra's shares sag ahead of results early Thurs
Conagra Brands Inc's CAG.N shares down 1.7% at $29.06 on Weds ahead of fiscal Q3 report due Thurs before market open. The packaged foods firm's fiscal third quarter results are expected to be down 2.5%. Wall Street concerned increased use of weight-loss drugs will crimp sales.
Reuters · 04/03 17:58
Edesa Biotech Engages Investors at Global Conferences
TipRanks · 04/02 13:38
Weekly Report: what happened at EDSA last week (0325-0329)?
Weekly Report · 04/01 10:54
Weekly Report: what happened at EDSA last week (0318-0322)?
Weekly Report · 03/25 10:56
Edesa Biotech Shines at Autoimmune Conference
TipRanks · 03/22 04:37
Weekly Report: what happened at EDSA last week (0311-0315)?
Weekly Report · 03/18 10:55
Weekly Report: what happened at EDSA last week (0304-0308)?
Weekly Report · 03/11 10:52
Edesa Biotech Showcases Innovations at Healthcare Conference
TipRanks · 03/07 21:07
BUZZ-U.S. STOCKS ON THE MOVE-Sea, AeroVironment, Vivid Seats
U.S. Stock index futures dipped on Tuesday. Dow e-minis were down 0.12% at 38,977. The top three NYSE percentage gainers premarket were Sea, AeroVironment and Vivid Seats. Investors await economic data and key events this week.
Reuters · 03/05 12:17
Edesa Biotech Showcases Innovations at Dermatology Events
TipRanks · 03/05 04:07
Weekly Report: what happened at EDSA last week (0226-0301)?
Weekly Report · 03/04 10:55
Weekly Report: what happened at EDSA last week (0219-0223)?
Weekly Report · 02/26 11:05
Weekly Report: what happened at EDSA last week (0212-0216)?
Weekly Report · 02/19 11:07
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Edesa Biotech (EDSA) and Ocular Therapeutix (OCUL)
Analysts have new ratings on Incyte, Edesa Biotech and Ocular Therapeutix. Morgan Stanley has maintained a Hold rating on incyte with a price target of $64.00. The analysts have also reiterated their Buy ratings on the Healthcare sector.
TipRanks · 02/14 11:30
Weekly Report: what happened at EDSA last week (0205-0209)?
Weekly Report · 02/12 10:58
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.